An Introduction to Cancer Immunotherapy
Inflammatory immune cells are involved in tumour development and dissemination. As the tumour develops, cancer cells evolve different mechanisms in order to evade attack, by avoiding the immune recognition and developing an immunosuppressive microenvironment. Harnessing the patient’s immune system to attack the tumour is the key principle of immunotherapy. Several classes of immunotherapies including cytokines, monoclonal antibodies against immune checkpoints, autologous dendritic cells expressing tumour antigen, genetically engineered oncolytic viruses and T-cells engineered to expressed chimeric antigen receptors (CAR-T cells), have been approved for many cancer subtypes, including solid tumours and haematological malignancies. Current challenges include elucidating predictive biomarkers, since many people fail to respond to these therapies.
Browse video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences. This is complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Cancer Immunotherapy Content
Hans Prenen, ASCO GI 2021: Non-gene Edited Allogeneic CAR T Cell Therapy
TouchIMMUNOLOGY got the chance to catch up with Hans Prenen (University Hospital Antwerp, Edegem, Belgium) around the potential advantages of non-gene edited allogeneic CAR T cell therapy (Clinical Trial Identifier: NCT03692429). The abstract ‘Updated data from alloSHRINK phase I first-in-human study evaluating CYAD-101, an innovative non-gene edited allogeneic CAR-T in mCRC.’ (ABSTRACT NUMBER: 74) was […]
Ken Kato, ASCO GI 2021: Developments in Nivolumab in Gastrointestinal Cancers
TouchIMMUNOLOGY were delighted to talk to Ken Kato at ASCO’s virtual Gastrointestinal Cancers Symposium 2021 to discuss the potential role of nivolumab in the treatment of gastrointestinal cancers, and how the identification of biomarkers is key to improve clinical response. For more information on the 5-year follow-up data presented at ASCO’s Gastrointestinal Cancer’s Symposium, please […]
Hyun C Chung, ASCO GI 2021: Lenvatinib plus Pembrolizumab in Patients with Advanced Solid Tumours
We were delighted to talk to Hyun C Chung (Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea) about the combination of lenvatinib plus pembrolizumab in the treatment of patients with advanced solid tumours (Clinical Trial Identifier: NCT03797326). The abstract ‘LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously […]
A patient’s journey through the immuno-oncology treatment landscape in melanoma
Watch leading experts explore the impact of immunotherapy incorporating PD-1 blockade on the treatment landscape and patient experience in melanoma.
- Discuss factors to consider when selecting PD-1 inhibitors to treat melanoma
- Understand the rationale for combination regimens incorporating PD-1 blockade
- Analyse the role of long-term clinical and real-world data in informing treatment decisions
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!